Publications by authors named "Daigo Saito"

Claim this Profile
L
Long-term effects of ipragliflozin and pioglitazone on metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes: 5 year observational follow-up of a randomized, 24 week, active-controlled trial: Effect of ipragliflozin in MASLD.
Daisuke Ito, Satoshi Shimizu, Akifumi Haisa, Shinnosuke Yanagisawa, Kazuyuki Inoue, Daigo Saito

J Diabetes Investig· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pheochromocytoma With High Adrenocorticotropic Hormone Production Capacity Without Pigmentation and Cushingoid Symptoms: A Case Report With a Literature Review.
Gen Mizutani, Masashi Isshiki, Eisuke Shimizu, Daigo Saito, Akira Shimada

Cureus· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and Characterization of Hypervalent Pentacoordinate Carbon Compounds Bearing a 7-6-7-Ring Skeleton.
Yohsuke Yamamoto, Yuan Shi, Takashi Masui, Daigo Saito, Tatsuya Inoue

Chemistry· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of Dapagliflozin Compared with Sitagliptin and Metformin in Drug-Naïve Japanese Patients with Type 2 Diabetes: A 12-Week, Open-Label, Randomized, Active-Controlled Trial.
Daisuke Ito, Kazuyuki Inoue, Daigo Saito, Keiko Hamaguchi, Kimie Kaneko

Diabetes Ther· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anagliptin Monotherapy for Six Months in Patients With Type 2 Diabetes Mellitus and Hyper-Low-Density Lipoprotein Cholesterolemia Reduces Plasma Levels of Fasting Low-Density Lipoprotein Cholesterol and Lathosterol: A Single-Arm Intervention Trial.
Yuichi Ikegami, Yasuhiro Takenaka, Daigo Saito, Akira Shimada, Ikuo Inoue

J Clin Med Res· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of dapagliflozin on renin-angiotensin-aldosterone system under renin-angiotensin system inhibitor administration.
Masashi Isshiki, Ichiro Sakuma, Yasuaki Hayashino, Takashi Sumita, Kazuo Hara, Daigo Saito

Endocr J· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Examination of Malignant Findings of Thyroid Nodules Using Thyroid Ultrasonography.
Daigo Saito, Ritsuko Nakajima, Shigemitsu Yasuda

J Clin Med Res· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Sudden Onset of Severe Thrombocytopenia While Using Evolocumab.
Ikuo Inoue, Yasuhiro Takenaka, Yoshitora Kin, Satoshi Yamazaki, Yuichi Ikegami, Daigo Saito

Case Rep Hematol· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical characteristics of anti-glutamic acid decarboxylase antibody-positive fulminant type 1 diabetes.
Daigo Saito, Yoichi Oikawa, Gen Mizutani, Kazuyuki Inoue, Masako Hatano

Endocr J· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Detailed Time Course of Decline in Serum C-Peptide Levels in Anti-Programmed Cell Death-1 Therapy-Induced Fulminant Type 1 Diabetes.
Daigo Saito, Yoichi Oikawa, Yuya Yano, Yuichi Ikegami, Atsushi Satomura

Diabetes Care· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intrinsic insulin secretion capacity might be preserved by discontinuing anti-programmed cell death protein 1 antibody treatment in 'anti-programmed cell death protein 1 antibody-induced' fulminant type 1 diabetes.
Gota Sakai, Daigo Saito, Ritsuko Nakajima, Masako Hatano, Yuichi Noguchi

J Diabetes Investig· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of Ipragliflozin and Pioglitazone Effects on Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Randomized, 24-Week, Open-Label, Active-Controlled Trial.
Daisuke Ito, Satoshi Shimizu, Kazuyuki Inoue, Daigo Saito, Morifumi Yanagisawa

Diabetes Care· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis